Skip to main content

Risk for Suicidal Ideation Not Increased With Semaglutide

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 9, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 9, 2024 -- For individuals with overweight or obesity and type 2 diabetes, semaglutide is not associated with an increased risk for suicidal ideation compared with non-glucagon-like peptide 1 receptor (GLP1R) agonist antiobesity medications, according to a study published online Jan. 5 in Nature Medicine.

William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted a retrospective cohort study using electronic health records to examine the associations of semaglutide versus non-GLP1R agonist antiobesity medications with suicidal ideation. The study population included 240,618 patients with overweight or obesity; findings were replicated among 1,589,855 patients with type 2 diabetes.

The researchers found that the risks for incident and recurrent suicidal ideation were lower for patients with overweight or obesity receiving semaglutide versus non-GLP1R agonist antiobesity medications (hazard ratios, 0.27 and 0.44, respectively); the findings were consistent across sex, age, and ethnicity stratification. In patients with type 2 diabetes, similar findings were replicated.

"Further studies should evaluate the association of semaglutide and other GLP1R agonist medications with the incidence and recurrence of suicidality in other at-risk populations," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

High Social Media Use Tied to Depression in Only Some Teens

TUESDAY, July 2, 2024 -- High social media use is only tied to increased depression in teens who are already vulnerable, according to a study published online June 26 in...

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...

Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea

FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.